Banco Santander Boosts Stake in Regeneron Pharmaceuticals

Banco Santander S.A. increases its holdings in the biopharmaceutical company by over 260%

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

Banco Santander S.A. has significantly increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 263.7% in the 3rd quarter, according to a recent 13F filing with the Securities & Exchange Commission. The firm now owns 71,135 shares of the biopharmaceutical company's stock, worth nearly $40 million.

Why it matters

Regeneron is a prominent biopharmaceutical company known for its innovative drug discovery technologies and pipeline of therapies. Banco Santander's increased investment suggests confidence in Regeneron's long-term growth potential within the pharmaceutical industry.

The details

According to the 13F filing, Banco Santander purchased an additional 51,577 shares of Regeneron during the quarter, bringing its total holdings to 71,135 shares. This represents about 0.07% ownership of the company. The increased stake makes Banco Santander one of Regeneron's larger institutional investors.

  • Banco Santander increased its Regeneron holdings in the 3rd quarter of the year.

The players

Banco Santander S.A.

A major Spanish multinational commercial bank and financial services company.

Regeneron Pharmaceuticals, Inc.

An American biotechnology company that discovers, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Got photos? Submit your photos here. ›

The takeaway

Banco Santander's substantial increase in its Regeneron holdings reflects the bank's confidence in the biopharmaceutical company's long-term growth prospects. This investment highlights Regeneron's standing as a leader in innovative drug development within the pharmaceutical industry.